Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2013 Aug;98(8):1168-72.
doi: 10.3324/haematol.2013.090381.

What challenges remain in chronic myeloid leukemia research?

Angelo M Carella, Susan Branford, Michael Deininger, Francois X Mahon, Giuseppe Saglio, Anna Eiring, Jamshid Khorashad, Thomas O'Hare, John M Goldman
Editorial

What challenges remain in chronic myeloid leukemia research?

Angelo M Carella et al. Haematologica. 2013 Aug.
No abstract available

PubMed Disclaimer

References

    1. Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109(6):2303–9 - PubMed
    1. Cortes JE, Maru A, De Souza CA, Guilhot F, Duvillie L, Powell C, et al. Bosutinib versus Imatinib in newly diagnosed chronic phase chronic myeloid leukemia – BELA trial: 24-month follow-up. Blood. 2011;118: Abstract 455.
    1. Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G, et al. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood. 2009;114(24):4933–8 - PubMed
    1. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251–9 - PubMed
    1. Kantarijan H, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Superiority of Nilotinib versus Imatinib for the treatment of patients newly diagnosed chronich phase Ph+ chronic myeloid leukemia: 24-month minimum follow-up of the phase 3 randomized ENESTnd study. Lancet Oncol. 2011;12(9):841–51 - PubMed

Publication types

MeSH terms